After 50 years of conventional phacoemulsification, Iantech introduces a micro-interventional devices designed to deliver energy-free endocapsular lens fragmentation. At Iantech, we are working to invent new surgical approaches designed to address the global footprint of cataract blindness. Using smart, efficient and adaptable micro-interventional technology, our team is building a new surgical platform.
Microstents and MIGS intervention have already changed the paradigm of glaucoma treatment. Iantech has taken micro-interventional technology by applying advanced micro-engineered memory shaped materials and instrumentation for mechanical, energy-independent cataract disassembly. The miLOOP™ Device is the first in a line of ophthalmic tools engineered by Iantech for its micro-interventional cataract surgery platform. Using micro-thin super-elastic, self expanding nitinol filament technology, the miLOOP™ device is designed to offer cataract surgeons the ability to achieve full thickness lens fragmentation for any grade cataract minimizing the intraocular ultrasonic vibrations and phaco power. Using micro-thin super-elastic, self expanding nitinol filament technology, miLOOP™ offers cataract surgeons the potential to achieve full thickness lens fragmentation for any grade cataract minimizing the intraocular application of ultrasonic vibrations and phaco power to the delicate ocular tissues.
The miLOOP™ device is designed to achieve full-thickness fragmentation of the nucleus independent of phaco energy using a super-elastic thin-filament. It is engineered to minimize capsular stress by using centripetal, out-in nucleus disassembly while conventional techniques employ centrifugal, in-out lens cutting with adjunct phaco-energy. The miLOOP™ lens fragmentation is done under full viscoelastic chamber stability protection and no simultaneous irrigation and aspiration.
miLOOP allows me to fragment the lens making my phaco technique easier” - Bill Trattler, MD
miLOOP allows me to fully fragment the lens with a peripheral approach, gently sweeping the cortex away from the capsule and disengaging the lens segments from the periphery, making them more accessible during phaco” – Jason Jones, MD
miLOOP exceeded my expectations… we evaluate a lot of technologies, and most do not exceed expectations… Now that I know what miLOOP can do for certain segments of my patients, it is an indispensable part of my surgical toolbox” – John Berdahl, MD
I was impressed with miLOOP’s ease of use and its possible disruptive potential in our space” – Bill Wiley, MD
individual results may vary
The miLOOP™ device is a micro-interventional instrument, which is designed to work in harmony with conventional phaco techniques for a more synergistic cataract procedure. The miLOOP device plus standard phaco = miPHACO surgical procedure
Explore our video library to learn more about the miLOOP™!
The miLOOP™ device is engineered to assist global outreach and humanitarian cataract efforts. Micro-interventional pen-like device is designed to support efforts to erase global blindness and to positively impact public health efforts in the 25 million blindness epidemic worldwide.
Dr. MacDonald and Dr. Ianchulev have pioneered the first miLOOP™ device missions in Panama and Tanzania. A new miLOOP™ device technique uses a no stitch 4mm scleral tunnel and is adoptable by cataract surgeons worldwide for sustainable global outreach!
Green box data: average long-term loss of corneal endothelium due to phaco surgery
Dr. MacDonald and Dr. Ianchulev have pioneered the first miLOOP™ missions in Panama and Tanzania. A new miLOOP™ technique with a 4mm scleral tunnel can not only make cataract surgery minimally invasive with improved clinical outcomes but can train cataract surgeons worldwide for sustainable global outreach!
people blind from advanced cataracts
of global blindness is from untreated cataracts
average loss of corneal endothelium due to phaco surgery
The Iantech Team has been at the center of breakthrough innovation in ophthalmology and has helped bring to life some of the greatest ophthalmic technologies over the last decade – with hundreds of thousands of patients benefiting every year – from Lucentis to intraoperative aberrometry to MIGS supraciliary stenting and now micro-interventional cataract surgery
Mr. Rockman started his career at J.P. Morgan, where he advised universities, research institutes, charitable foundations and other non-profit organizations on a wide variety of financing activities over more than 10 years in the firm’s investment banking division. His time at J.P. Morgan also included three years with the firm’s Social Finance group, which has been a pioneer in the emerging field of impact investing. After working closely with the Bill & Melinda Gates Foundation to structure and launch the Global Health Investment Fund, he left J.P. Morgan in 2014 to join the GHIF investment management team. He received an AB from the Woodrow Wilson School of Public and International Affairs at Princeton University.
Micro-interventional phaco surgeons achieve superior outcomes in the most difficult cases using the breakthrough miLOOP™ device. The combined procedure of miLOOP™ nucleus disassembly and phaco-emulsification (aka miPHACO), was studied in a randomized controlled investigation (LEEP 103) comparing clinical outcomes and surgical efficiency to conventional phaco surgery. miPHACO with the miLOOP™ device statistically improved surgical performance with a significant reduction in burst phaco energy and fluidics delivered to the eye. The miLOOP™ device facilitated lens fragmentation, augmented cortical dissection and ultimately led to more efficient phacoemulsification.